| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BULLION GOLD DISCOVERIES Aktie jetzt für 0€ handeln | |||||
| 09.07. | Bullion Gold Discoveries Corp: Bullion Gold private placement | 1 | Stockwatch | ||
| 30.06. | Bullion Gold Discoveries Corp: Bullion Gold samples 5.4 g/t Au at Terragold project | 1 | Stockwatch | ||
| 30.06. | Bullion Gold Discoveries Corp.: Bullion Reports 5.4 g/t Au and 5.0 g/t Ag in Surface Grab Sample and Commences Validation Drilling at Terragold | 375 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 30, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to provide an exploration update from Bullion's flagship and... ► Artikel lesen | |
| 23.06. | Bullion Gold Discoveries Corp: Bullion shareholders approve all matters at AGM | 1 | Stockwatch | ||
| 23.06. | Bullion Gold Discoveries Corp.: Bullion Announces Results of Annual General Meeting | 729 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 22, 2026) - Bullion Gold Discoveries Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to announce the voting results from its Annual General Meeting... ► Artikel lesen | |
| 18.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 18.06.2026 | 397 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.06.2026
Aktien
1 SE0029278985 Tangen Industrikapital... ► Artikel lesen | |
| 17.06. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.06.2026 | 413 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 17.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.06.2026ISIN NameCA1202272029 BULLION... ► Artikel lesen | |
| 17.06. | Bullion Gold Discoveries Corp: Bullion Gold closes $2-million private placement | 1 | Stockwatch | ||
| 17.06. | XFRA ISIN CHANGE | 262 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA1202272029 Bullion Gold Discoveries Corp. 17.06.2026 CA1199331093 Bullion Gold Discoveries Corp. 18.06.2026 Tausch... ► Artikel lesen | |
| 17.06. | Bullion Gold Discoveries Corp.: Bullion Closes $2M Private Placement | 408 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Bullion Gold Discoveries Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to announce that it has closed its previously announced non-brokered... ► Artikel lesen | |
| 17.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.06.2026 | 316 | Xetra Newsboard | Das Instrument EA20 NO0013601245 EAM SOLAR AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 17.06.2026 und ex Kapitalmassnahme am 18.06.2026 The instrument EA20 NO0013601245 EAM SOLAR AS NK... ► Artikel lesen | |
| 16.06. | XFRA B4R: AUSSETZUNG/SUSPENSION | 160 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBULLION GOLD RES... ► Artikel lesen | |
| 13.06. | Bullion Gold Resources Corp (2): Bullion Gold name change to Bullion Gold Discoveries | 6 | Stockwatch | ||
| 12.06. | Bullion Gold Resources Corp. kündigt Namensänderung an | 1 | GoldSeiten.de | ||
| 12.06. | Bullion Gold Resources Corp (2): Bullion Gold Resources to change name | 1 | Stockwatch | ||
| 11.06. | Bullion Gold Resources Corp.: Bullion Announces Name Change to Bullion Gold Discoveries Corp | 570 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 11, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to announce that it will complete a name change from "Bullion... ► Artikel lesen | |
| 09.06. | Bullion Gold Resources Corp (2): Bullion Gold moves field crew to Terragold | 1 | Stockwatch | ||
| 09.06. | Bullion Gold Resources Corp.: Bullion Mobilizes Field Team to Terragold Project and Increases Private Placement to $2 Million | 405 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 9, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to announce that its field team has been mobilized to Bullion's... ► Artikel lesen | |
| 02.06. | Bullion Gold Resources Corp (2): Bullion arranges $1.5-million private placement | 2 | Stockwatch | ||
| 02.06. | Bullion Gold Resources Corp.: Bullion Announces $1.5 Million Private Placement | 369 | Newsfile | Montreal, Quebec--(Newsfile Corp. - June 2, 2026) - Bullion Gold Resources Corp. (TSXV: BGD) ("Bullion" or the "Company") is pleased to announce a private placement of up to 16,666,667 units of... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,07 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| KINIKSA PHARMACEUTICALS | 74,34 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 16,520 | 0,00 % | Monte Rosa, BioAge plunge as Novo's setback casts a shadow over pipeline | ||
| EDGEWISE THERAPEUTICS | 38,430 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,93 | +0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| COGENT BIOSCIENCES | 38,910 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 55,89 | 0,00 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,030 | -3,05 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| DYNE THERAPEUTICS | 25,180 | -2,14 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 29,820 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| ERASCA | 18,150 | -2,84 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 103,39 | -3,38 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 20,330 | +0,10 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,195 | +0,06 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |